| Description | Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, thereby blocking the interaction of this domain with the FXa active site. Injections of Concizumab increase thrombin in the blood and can be used to prevent and treat hemophilia. |
| In vitro | Concizumab以浓度依赖的方式提高凝血酶的峰值[1]。 |
| In vivo | 在猕猴体内，Concizumab（静脉注射/皮下注射）阻断了TFPI与FXa活性部位的相互作用[2]。 |
| Synonyms | mAb 2021, NN 7415 |
| molecular weight | N/A |
| CAS | 1312299-39-0 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Kjalke M, et al. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses. J Thromb Haemost. 2021 Jul;19(7):1687-1696. 2. Agersø H, et al. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration. Eur J Pharm Sci. 2014 Jun 2;56:65-9. |